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By far, only tigecycline, colistin, and some aminoglycosides still show favorable in vitro
activities against carbapenem-resistant Enterobacteriaceae. However, rapid emergence
of resistance often occurs during long-term treatment in clinic, challenging these last
resort antimicrobials. In this study, we measured mutant prevention concentration (MPC)
and mutant selection window (MSW) of tigecycline, colistin and amikacin alone and in
combination for clinical isolates of KPC-producing K. pneumoniae, and characterized
the resistant mutants recovered. The MPC90 of 30 tested isolates for tigecycline,
colistin, and amikacin were 16, >128, and 128 mg/L, respectively. The average MSW
of tigecycline-amikacin, tigecycline-colistin, and amikacin-colistin combinations for four
representative strains were 11.99, 200.13, and 372.38, respectively. A strong correlation
was found between the MSWcombination and the product of MSW of each single drug.
Combinations of 1 minimal inhibitory concentration (MIC) multiple tigecycline and 1 MIC
multiple amikacin could result in 1000- to 10000-fold reduction in mutational frequency
relative to their individual mutational frequencies, and combinations of 1 MIC multiple
amikacin and 1.5–2 MIC multiple tigecycline could successfully restrict the recovery of
resistant mutants on agar plates. However, 2 MIC multiple colistin in combination with 2
MIC multiple tigecycline or amikacin merely resulted in approximately 10-fold decrease
in the mutational frequency. In conclusion, this study showed tigecycline-amikacin
combination could effectively suppress the selection of resistance at low concentrations
compared with the colistin-tigecycline and colistin-amikacin combinations, suggesting
that this combination may be useful in clinical therapy.
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INTRODUCTION
The worldwide emergence and dissemination of carbapenem-resistant Enterobacteriaceae (CRE),
particularly Klebsiella pneumoniae producing Klebsiella pneumoniae carbapenemase (KPC),
represents a serious threat to public health (Munoz-Price et al., 2013). Besides carbapenems, these
superbugs often carry genes that confer high levels of resistance to many other broad-spectrum
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antibiotics (Hirsch and Tam, 2010). By far, only a few agents, such
as tigecycline, colistin and some aminoglycosides show favorable
in vitro activities against CRE (Hirsch and Tam, 2010). However,
due to the wide use, resistance has challenged these last-resort
treatment options (Capone et al., 2013; Monaco et al., 2014;
Giske, 2015).
Since the pace of developing new effective antibiotics is
quite slow, suppressing further resistance emergence of current
available agents is of the great significance. Selective enrichment
and amplification of resistant mutant isolates most likely
occurs when antimicrobial concentrations fall in a specific
range called the mutant selection window (MSW). The lower
boundary of the MSW is approximate to the minimal inhibitory
concentration (MIC), and the upper boundary is the mutant
prevention concentration (MPC), which could prevent the
emergence of all least susceptible, single-step resistant mutant
subpopulations (Zhao and Drlica, 2008). The spontaneous single-
drug resistant mutants usually arise at a frequency from 10−6
to 10−8, and initially susceptible bacteria theoretically may
have a fairly low probability (<10−10) to develop mutations
causing resistance to both drugs for surviving at concentrations
above their respective MICs (Zhao and Drlica, 2001). Thus,
simultaneous administration of two antibiotics with different
modes of action (without occurrence of cross-resistance) may
suppress the selection of resistant mutants (Zhao and Drlica,
2001). In addition, many studies have reported favorable
clinical outcomes and lower mortality rates for patients treated
with combination therapies (Falagas et al., 2014; Ni et al.,
2015). Therefore, for improving the efficacy and preventing the
emergence of further resistance, most clinicians recommend
using combination therapies to treat CRE infections (Rafailidis
and Falagas, 2014).
The aim of this study was to determine the in vitro effects of
tigecycline, colistin and amikacin alone and in combination on
recovery of resistant mutants of KPC-producing K. pneumonia,
and to predict the ability of different antibiotic combinations
on the prevention of resistance emergence during treatment in
clinic.
MATERIALS AND METHODS
Bacterial Strains and Antimicrobial
Agents
Sixty-eight identified KPC-producing K. pneumoniae strains
were isolated from different patients during the period June –
December 2014 from the department of clinical microbiology
in two tertiary hospitals in Beijing, China. Escherichia coli
ATCC25922 was used as a reference strain. All strains were
identified using the Vitek R© 2 Compact System (bioMérieux,
Marcyl’Étoile, France).
Tigecycline and colistin standards were purchased from
Sigma-Aldrich (St Louis, MO, USA). Amikacin standard
was obtained from the National Institute for the Control
of Pharmaceutical and Biological Products (NICPBP, Beijing,
China). All the agents were prepared as fresh stock solutions in
sterile distilled water on the day of use.
This study was performed in a standard Microbiological Lab
in our hospital. We handle the clinical isolates according to the
WHO Laboratory Biosafety Manual (WHO, 2004).
Determination of the MICs
The MICs of tigecycline, colistin, and amikacin were determined
by the agar dilution method according to CLSI (2014) guidelines.
In brief, Mueller Hinton agar (Difco, Franklin Lakes, NJ, USA)
plates containing a series of twofold concentration increments
of each agent were prepared according to specifications. Then,
approximate 104–105 CFU bacterial cells were inoculated by an
autoclaved replicator and incubated at 35◦C in ambient air for
20 h. The MIC was defined as the lowest drug concentration that
inhibited the visible growth of colonies. All MIC determinations
were conducted at least in triplicate on separate days. The
MIC breakpoints of susceptibility for the three antibiotics
were interpreted in accordance with the European Committee
on Antimicrobial Susceptibility Testing standards (EUCAST):




In Brief, each strain underwent Enterobacterial Repetitive
Intergenic Consensus-PCR (ERIC-PCR) typing as described
previously (Smith et al., 2007; Ying et al., 2015).The primer
pair ERIC1 and ERIC2 (Supplementary Table 1) were used to
amplify intervening fragments of ERIC in the genomic DNA.
Each reaction contained 2.5 µl of 10x PCR buffer, 2 µl dNTP
mixture, 0.125 µl Taq enzyme, 0.5 µl each primer (10 µmol/L)
and 1 µl DNA template, added to a final volume of 25 µl
with ddH2O. Thermal cycling was performed in an ABI 2700
thermal cycler (Applied Biosystems, Carlsbad, CA, USA): initial
incubation at 94◦C for 7 min; 30 cycles of 30 s at 94◦C, 1 min
at 52◦C, and 8 min at 65◦C; and a final incubation at 65◦C for
10 min. The amplified products were resolved in 1.2% agarose
gel electrophoresis stained with ethidium bromide. The data were
analyzed with the software package BioNumerics 5.1 (Applied
Maths, Austin, TX, USA) as previously described (Smith et al.,
2007).
Determination of the MPCs and
Frequency of Resistant Mutants
The MPCs of drugs alone and in combinations were determined
by methods described previously (Zhanel et al., 2006; Ni et al.,
2013). In brief, bacterial cells were grown overnight in fresh
Mueller-Hinton broth (MHB) with vigorous shaking at 35◦C in
ambient air. Then the overnight cultures were diluted by 10-
fold with MHB, and incubated at 35◦C for 6 h. The growth
was centrifuged (4000 × g for 5 min) to yield a high-density
culture containing cells of ∼3 × 1010 CFU/ml. Fifty microliters
of samples (approximate 1.5 × 109 cells) were inoculated
onto Mueller-Hinton agar plates (diameter, 90 mm) containing
different concentrations of tigecycline, colistin and amikacin
alone or in combination. For a given drug concentration, seven
plates were used to ensure that the total number of cells tested was
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at least 1010. For counting the number of resistant colonies arising
at a given concentration, another eight plates was inoculated with
different number of bacterial cells (103, 105, 107, and 108). At
the same time, the cell density of the culture was determined
retrospectively by applying serial dilutions to drug-free agar
plates. All plates were incubated at 35◦C in ambient air for
3 days. The MPC was defined as the concentration that blocked
growth when at least 1010 cells were applied to agar plates. The
number of colonies arising in each plate of a given concentration
was counted (if it was countable, typically,<500 CFU per plate)
and the frequency of resistant mutants was defined as the total
number of colonies in all plates with countable colonies divided
by the total number of cells plated on these specific plates.
Measurement of the MSWs of Single
Drugs and Combinations
As mentioned above, the MSW of a single drug is a concentration
range which approximately extends from the MIC to MPC,
denoted by double-headed arrows in Figure 1A. The width of
MSW can be expressed as a ratio (MPC/MIC), which is also
termed as selection index (SI). As displayed in Figure 1B, no
resistant mutants can recover above the MPC curve, and the
MIC lines are approximate the lower boundary of the MSW in
combination therapy (Zhao and Drlica, 2002). Therefore, the
MSW of drug combinations (MSWcombination) can be measured
as the area that extends from the MPC curve to the MIC lines of
each drug (Zhao and Drlica, 2002).
Characterization of Resistant Mutants
For examining whether the arising colonies of each plate at
a given concentration contain stable resistant mutants, two
colonies of each plate were passaged five times on drug-free
agars, and then the MICs were determined by the agar dilution
methods. Real-time quantitative reverse transcription PCR (qRT-
PCR) was used to detect the expression levels of the eﬄux
pump gene acrB and the global transcriptional regulator ramA
in tigecycline-resistant mutants, the expression level of pmrK
that belongs to the pmrHFIJKLM operon in colistin-resistant
mutants and the eﬄux pump gene acrD in amikacin-resistant
mutants. The qRT-PCR was performed as previously described
(He et al., 2015). Briefly, overnight bacterial cultures were diluted
with MHB broth, and then were grown at 35◦C with shaking
of 200 rpm. Cell pellets were harvested at OD600 = 0.6. The
Purelink RNA Mini Kit (Ambion, Carlsbad, CA, USA) was used
for extracting ribonucleic acid (RNA). The yield and quality of
RNA were determined by a Nanodrop 2000C (Thermo, USA).
Then the total RNA was reverse transcribed into cDNA using
the PrimeScript RT Reagent kit (Tiangen, Beijing, China). Real-
time qRT-PCR was performed using a LightCycler 480 II (Roche,
Germany) with 40 cycles of 15 s at 95◦C, 20 s at 52◦C, and
30 s at 72◦C, and SYBR Premix Ex Taq (TaKaRa, Dalian,
China) was used to quantify the expression of the target gene.
Expression of each gene was normalized to that of a housekeeping
gene (rrsE). The parent strain was used as the reference strain.
Besides, the mgrB gene of the colistin-resistant mutants and the
aminoglycoside-modifying enzymes genes including aac (3)-I,
FIGURE 1 | A theoretical model of the mutant selection window (MSW).
(A) MSW of a single drug ranging from the MIC to the MPC; (B) The MSW
notion in drug combinations extends from the MPC curve to the MIC line
(dashed line).
FIGURE 2 | Electrophoretogram of PCR product in Enterobacterial
repetitive intergenic consensus sequence (ERIC) profiles of 30
KPC-producing Klebsiella pneumoniae clinical isolates investigated in
this study.
aac (3)-II, aac (3)-III, aac (6)-Ib, aac (6)-II, ant (2′′)-I, ant (3′′)-I,
and 16S rRNA methylase genes (armA, rmtA, rmtB, rmtC, rmtD,
npmA) of amikacin-resistant mutants was amplified by PCR,
and then the mgrB was sequenced by the Applied Biosystems
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TABLE 1 | MPCs distribution of three antimicrobials alone for 30 clinical isolates of KPC-producing Klebsiella pneumoniae.
Antimicrobials (µg/ml) 4 8 16 32 64 128 >128 MPC90 MPC90/MIC90
Tigecycline 6 11 12 1 32 8
Colistin 2 4 24 >128 >256
Amikacin 6 20 4 128 32
3730 sequence analyser (Applied Biosystems Inc., USA). In brief,
the whole-cell DNA was extracted using the TIANcombi DNA
Lyse & Det PCR Kit (Tiangen, Beijing, China) according to the
manufacturer’s instructions. Each reaction contained 2.5 µl of
10x PCR buffer, 2 µl dNTP mixture, 0.3 µl Taq enzyme (5 U/µl;
Tiangen, Beijing, China), 1 µl each primer (10 µmol/L) and 1 µl
DNA template and 17.2 µl ddH2O. The PCR method consisted
of initial incubation at 94◦C for 2 min; 35 cycles of 20 s at
94◦C, 20 s at 55◦C, and 30 s at 72◦C; and a final incubation at
72◦C for 10 min. The primers used in this study were shown in
Supplementary Table 1.
Statistical Analysis
MSWcombination of different drug pairs were compared and
their differences were determined by One-way ANOVA and
independent-sample t-test. We speculated the MSWcombination
might be associated with the MSW of each single drug. Therefore,
the relationship between the MSWs of single drugs and the
MSWcombination was evaluated by Pearson’s correlation analysis.
All analyses were performed with the software of SPSS 20.0.
A P-value < 0.05 was considered statistically significant.
RESULTS
MPCs and MSWs of Single Drugs
Among the 68 tested isolates, 85.3% (58 isolates) was susceptible
to tigecycline, 97.1% (66 isolates) was susceptible to colistin,
and 51.5% (35 isolates) was susceptible to amikacin. Thirty
isolates were susceptible to all the three drugs, and they were
mainly grouped into four clonal types (A, B, C, D) identified
by ERIC-PCR (Figure 2). The MPC distributions of the 30
isolates are listed in Table 1. The MPC90 for tigecycline, colistin,
and amikacin were 16, >128, and 128 mg/L, respectively. One
representative isolate of each clone type (Kp3 for A, Kp18 for B,
Kp8 for C, and Kp23 for D) was randomly selected for evaluating
the effect of antimicrobial concentrations on the selection of
resistant mutants. As shown in Figure 3, a distinct plateau region
was observed in the recovery curves of colistin. When the colistin
concentration increased from 2- to 16-fold of the MIC, the
frequency of resistant mutants did not decrease significantly.
MPCs and MSWs of Drug Combinations
The MPCs of three pairwise drug combinations were shown in
Figure 4. The average MSWcombination of tigecycline-amikacin,
tigecycline-colistin, and amikacin-colistin combinations for 4
strains were 11.99, 200.13, and 372.38, respectively. The
MSWcombination of tigecycline-amikacin combination was much
smaller than that of the other two combinations (P = 0.002).
FIGURE 3 | Effect of antimicrobial concentration on recovery of
mutants in K. pneumoniae strain Kp3 (filled circles), Kp18 (filled
squares), Kp8 (open circles), and Kp23 (open squares) were applied to
agar plates containing the indicated concentrations of tigecycline,
colistin or amikacin. Replicate experiments gave results similar to those
shown.
A correlation was found between the MSWcombination and the
product of MSW of each single drug (MSWA ×MSWB; r2 = 0.68,
P = 0.0153), and a strong correlation was found between
log2 MSWcombination and log2 (MSWA × MSWB; r2 = 0.96,
P < 0.0001; Figure 5).
Frontiers in Microbiology | www.frontiersin.org 4 August 2016 | Volume 7 | Article 1304
fmicb-07-01304 August 17, 2016 Time: 14:15 # 5
Ni et al. Tigecycline-Amikacin Combination on Resistance Selection
FIGURE 4 | Mutant selection window of drug combinations (MSWcombination) for four KPC-producing K. pneumoniae strains. MSWcombination can be
measured as the area that extends from the MPC curve (curves with symbols) to the MIC lines (dashed line). TIG, tigecycline; CST, colistin; AMK, amikacin.
Combinations of 1MIC multiple amikacin and 1.5–2
MIC multiple tigecycline could restrict the recovery of
resistant mutants on agar plates, while resistant mutants still
recovered on plates containing 1 MIC multiple amikacin
and 32 MIC multiple colistin in strain Kp3, Kp8, and
Kp23 (Figure 4). As displayed in Table 2, 2 MIC multiple
colistin in combination with 2 MIC multiple tigecycline or
amikacin merely resulted in approximately 10-fold decrease
in mutational frequency relative to their individual mutational
frequencies. By contrast, combinations of 1MIC multiple
tigecycline and 1MIC multiple amikacin could result in
1000- to 10000-fold reduction in mutational frequency for all
strains.
Characterization of Recovered Resistant
Mutants
The possible resistance mechanisms of recovered resistant
mutants from the Kp3 isolate were further characterized. As
shown in Figure 6, the average expression levels of ramA and
acrB genes for 20 tigecycline-resistant mutants (Kp3-T1 to Kp3-
T20) increased to 70.4 and 6.8 times compared with the parent
isolate. The average expression level of pmrK genes for colistin-
resistant mutants (Kp3-D1 to Kp3-D20) increased to 9.5 times
compared with the parent isolate. But the expression levels
of acrD genes were down-regulated in most amikacin-resistant
mutants. Nine colistin-resistant mutants were detected to carry
mutations in mgrB (GenBank accession numbers KX650149 for
Kp3-D3; KX650150 for Kp3-D4; KX650151 for Kp3-D5 and Kp3-
D8; KX650152 for Kp3-D6, Kp3-D13, Kp3-D15, and Kp3-D17;
KX650153 for Kp3-D18), whereas PCR results of three mutants
were negative. Because all the mutants were derived from the
same parent isolate, we deemed that these three colistin-resistant
mutants with negative PCR results had mutations in mgrB as well.
Of the amikacin-resistant mutants, none were detected to harbor
the screened aminoglycoside-modifying enzymes genes or 16S
rRNA methylase genes.
DISCUSSION
Although the process of antibiotic-resistance evolution is quite
complicated, and resistance may occur when bacteria are exposed
to quite low antibiotic concentrations, resistant mutants with
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FIGURE 5 | Relationship between the MSW of single drugs and the
MSW of drug combinations (MSWcombination). (A) Correlation between
MSWcombination and the product of MSW of each single drug (MSWA ×
MSWB); (B) Correlation between log2 MSWcombination and log2
(MSWA × MSWB).
strong phenotypes are much more likely selected under the
pressure of lethal drug concentrations (approximately from
MIC to MPC; Hughes and Andersson, 2012). Therefore, the
determination of MPC and MSW of a given antibiotic could be
useful in telling whether it is reasonable to use monotherapy
with great chance of resistant mutants emerging. Our study
showed the MPCs of tigecycline, amikacin and colistin for
KPC-producingK. pneumoniaewere very high. The outcomes are
FIGURE 6 | Relative expression levels of ramA, acrB, pmrK, and acrD
genes for resistant mutants of Kp3 recovered from the selection
pressure of three different drugs. TIG-R, tigecycline-resistant mutants;
CST-R, colistin-resistant mutants; AMK-R, amikacin-resistant mutants.
in agreement with recent studies which reported that the MPCs
of tigecycline and colistin for K. pneumoniae ranged between 4–
16 mg/L and >128 mg/L, respectively (Choi and Ko, 2014; Choi
et al., 2015). Moreover, we found a broad plateau in the recovery
curves of colistin, indicating that highly resistant subpopulations
could be easily selected at low drug concentrations. The in vitro
results might partly explain why the rapid development of
resistance to these agents during long-term monotherapy has
been frequently reported.
Many studies have demonstrated that combination therapy
could narrow or close the MSW, thereby minimizing or
preventing the selection of resistant bacterial cells (Zhanel
et al., 2006; Cai et al., 2012; Ni et al., 2013). We found just
like drug combinations displayed synergistic or antagonistic
effects on inhibiting bacterial growth, different combinations
also showed different ability to affect the evolution of resistance.
The addition of low-dose colistin to tigecycline or amikacin
could not decrease the recovery of resistant mutants, while
low-dose tigecycline-amikacin combination could significantly
reduce the mutational frequency. Lübbert et al. (2013) reported
that when both gentamicin and colistin were used for selective
digestive decontamination in patients with KPC-producing
K. pneumoniae, rapid emergence of secondary resistance to
gentamicin (45% patients) and colistin (19% patients) were
TABLE 2 | Mutational frequencies of drug-isolate combinations at 1 MIC and 2 MIC multiple.
Isolate MIC multiple TIG CST AMK TIG+ CST TIG+ AMK AMK+CST
Kp3 1× 2.07 × 10−5 8.52 × 10−5 1.79 × 10−5 4.15 × 10−6 7.04 × 10−9 4.52 × 10−7
2× 2.68 × 10−6 7.85 × 10−6 2.28 × 10−6 2.73 × 10−7 — 1.90 × 10−7
Kp18 1× 6.95 × 10−5 6.75 × 10−5 1.65 × 10−5 2.95 × 10−6 1.54 × 10−8 2.85 × 10−6
2× 1.86 × 10−7 3.18 × 10−6 3.93 × 10−6 6.50 × 10−8 — 5.02 × 10−7
Kp8 1× 6.83 × 10−5 5.45 × 10−5 2.75 × 10−5 4.18 × 10−6 6.28 × 10−8 4.16 × 10−6
2× 2.17 × 10−7 6.45 × 10−6 1.02 × 10−5 7.23 × 10−8 — 1.49 × 10−6
Kp23 1× 3.18 × 10−5 3.82 × 10−5 1.51 × 10−5 8.15 × 10−6 4.50 × 10−9 1.85 × 10−6
2× 8.17 × 10−7 4.93 × 10−6 9.24 × 10−7 4.36 × 10−8 — 6.76 × 10−7
TGC, tigecycline; CST, colistin; AMK, amikacin; —, no colony recovered.
Frontiers in Microbiology | www.frontiersin.org 6 August 2016 | Volume 7 | Article 1304
fmicb-07-01304 August 17, 2016 Time: 14:15 # 7
Ni et al. Tigecycline-Amikacin Combination on Resistance Selection
observed. Another two studies also reported that resistant
strains were isolated during the combination therapy of colistin
and tigecycline (Elemam et al., 2009; Cho et al., 2012).
Therefore, the combinations of colistin-tigecycline and colistin-
aminoglycosides may not effectively suppress the selection of
resistant mutants when treating KPC-producing K. pneumoniae
infections in clinic. In addition, we found a strong correlation
between the MSWcombination and the MSW of individual drugs.
This suggests that combinations including individual drug
constituents with smaller MSWs may have better ability in
preventing the evolution of resistance.
In our study, relatively increased expression levels of acrB
and ramA genes were detected in all tigecycline-resistant
mutants. These results are consistent with the notion that
up-regulation of eﬄux pumps is associated with tigecycline
resistance in Gram-negative bacteria (Wang et al., 2015).
Previous studies found the inactivation or down-regulation of
mgrB gene is responsible for colistin resistance in K. pneumoniae
of clinical origin (Cannatelli et al., 2014; Poirel et al., 2015).
Among 20 tested colistin-resistant mutants in this study,
mutations in mgrB genes were also identified in 12 mutants.
No aminoglycoside-modifying enzymes genes or 16S rRNA
methylase genes were detected in amikacin-resistant mutants.
Though the eﬄux pump AcrD was shown to participate
in the eﬄux of aminoglycosides (Rosenberg et al., 2000),
interestingly, the acrD gene of resistant mutants were down-
regulated in this study. The spontaneous resistance to amikacin
might involve other mechanisms, such as inadequate drug
transport and alterations of target ribosomal binding sites (Bryan,
1988).
Limitations exists in our study. In clinical conditions,
K. pneumoniae can acquire resistance via chromosomal
mutations and lateral gene transfer (Smith et al., 2003).
Our study could not reflect the whole complicated clinical
picture, because MPCs/MSWs derived from chromosomal
mutations but not lateral gene transfer. Additionally,
constant antibiotic concentrations were used throughout
this in vitro study, and we neglected the influence of
in vivo immunity on resistance selection. Therefore, studies
using ideally animal models are needed to confirm these
findings.
CONCLUSION
The wide MSWs of tigecycline, colistin, and amikacin for
KPC-producing K. pneumoniae suggest the possibility of
rapid emergence and spread of resistance during long-term
monotherapy in medical practice. Compared with the colistin-
tigecycline and colistin-amikacin combinations, the tigecycline-
amikacin combination can effectively suppress the selection
of resistance at low concentrations. Combinations including
individual drug constituents with smaller MSWs may have better
ability in preventing the evolution of resistance in clinic.
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